Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.38 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3053958 | 1.00 | TDP1 (0.41) | TDP1HTR1AKMT2ALPAR1LPAR5 | |
| SCHEMBL3058403 | 0.91 | HTR1A (0.47) | HTR1AKMT2AHCRTR1HCRTR2MEN1 | |
| SCHEMBL3045271 | 0.91 | HTR1A (0.47) | HTR1AKMT2AHCRTR1HCRTR2MEN1 | |
| SCHEMBL3059938 | 0.91 | HTR1A (0.47) | HTR1AKMT2AHCRTR1HCRTR2MEN1 | |
| SCHEMBL3040851 | 0.87 | NPY5R (0.41) | HTR1AHCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL3053994 | 0.87 | NPY5R (0.41) | HTR1AHCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL3052731 | 0.86 | HCRTR1 (0.39) | TDP1HTR1AKMT2AHCRTR1HCRTR2 | |
| SCHEMBL3057175 | 0.86 | HCRTR1 (0.39) | TDP1HTR1AKMT2AHCRTR1HCRTR2 | |
| SCHEMBL3055358 | 0.86 | MAPK14 (0.47) | KMT2A | |
| SCHEMBL3055134 | 0.86 | MAPK14 (0.47) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | CYP11B2, CYP11B1, BBC3 | TDP1 1379/4885HTR1A 1265/4885KMT2A 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.